1. This list refers to pyridine compounds used as therapeutic agents for central nervous system disorders related to phosphoric acid 10. This report also deals with the use of these compounds in the treatment of neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, as well as diseases related to low physical fitness or matrix necrosis in females. 1. Characteristic 1: a compound of formula (1), wherein: A is selected from a group consisting of (1) pyridine (2) quinoolinilo, (3) naftiridinil, (4) tiazollo, (5) piridizilo,(V I) oxazolilo, y (V II) pirazolilo, (V III) dihydropirolopiazolilo, (I x) dihydrocycloopentapiridinil, (x) imidazopiridininilo y (XI) pirazopirimidinilo； B. selected as: (I) tiazolilo, (II) pirazolilo, (III) tiadiazolilo, (I V) isoxazolilo, (V) isotiazolilo, (VI) piridilo y (VII) pirimidinilo； 9174l；R¹ᵇ and R¹ᶜ are independently selected from the group consisting of: (i) hydrogen, (ii) halogen, (iii) hydroxyl, (iv) - (C = O) ₘ-Oₙ-C₁₋₆-alkyl,In case m is 0 or 1, n is 0 or 1 (if M is 0 or 0, there is a link), in this case, asphalt is not replaced or replaced with one or more alternatives selected in R3 1,(V) - (C 3DO) -O -cicloalquilo CWhere cyclopentanediol is not replaced or replaced by one or more alternatives selected in R3,(Vi) - (C 3DO) -alquenilo COne or more alternatives selected between R3 are not used to replace or replace aldicarb,(VII) - (C = O) 8344； - asphalt c832283331；Asphalt is not replaced or replaced by one or more substitutes selected from R3,(VIII) - (C = O) 8344； - phenyl o - (C = O) 8344； - O 8345； - naftillo, in which phenyl or northwest non-n-propylformic acid is not replaced by one or more alternatives selected from R3,(IX) - (C = O) 8344； - O 8345； - heterogeneous, in which one or more alternatives selected from R1 cubic meters are not replaced or replaced,(X) - (C 3DO) -NR R(Xi) -S (O) -NR R(Xii) -S (O) q-RQ is 0, 1 or 2, R1 is selected from the definitions of R1 83044 and R1,(xii
